Neuronal nitric oxide synthase (nNOS) splice variant function: Insights into nitric oxide signaling from skeletal muscle

Jordan E. Balke, Ling Zhang, Justin M. Percival

Research output: Contribution to journalReview article

4 Citations (Scopus)

Abstract

Defects in neuronal nitric oxide synthase (nNOS) splice variant localization and signaling in skeletal muscle are a firmly established pathogenic characteristic of many neuromuscular diseases, including Duchenne and Becker muscular dystrophy (DMD and BMD, respectively). Therefore, substantial efforts have been made to understand and therapeutically target skeletal muscle nNOS isoform signaling. The purpose of this review is to summarize recent salient advances in understanding of the regulation, targeting, and function of nNOSμ and nNOSβ splice variants in normal and dystrophic skeletal muscle, primarily using findings from mouse models. The first focus of this review is how the differential targeting of nNOS splice variants creates spatially and functionally distinct nitric oxide (NO) signaling compartments at the sarcolemma, Golgi complex, and cytoplasm. Particular attention is given to the functions of sarcolemmal nNOSμ and limitations of current nNOS knockout models. The second major focus is to review current understanding of cGMP-mediated nNOS signaling in skeletal muscle and its emergence as a therapeutic target in DMD and BMD. Accordingly, we address the preclinical and clinical successes and setbacks with the testing of phosphodiesterase 5 inhibitors to redress nNOS signaling defects in DMD and BMD. In summary, this review of nNOS function in normal and dystrophic muscle aims to advance understanding how the messenger NO is harnessed for cellular signaling from a skeletal muscle perspective.

Original languageEnglish (US)
Pages (from-to)35-47
Number of pages13
JournalNitric Oxide - Biology and Chemistry
Volume82
DOIs
StatePublished - Jan 1 2019

Fingerprint

Nitric Oxide Synthase Type I
Muscle
Nitric Oxide
Skeletal Muscle
Cell signaling
Phosphodiesterase 5 Inhibitors
Sarcolemma
Neuromuscular Diseases
Defects
Duchenne Muscular Dystrophy
Golgi Apparatus
Protein Isoforms
Cytoplasm
Muscles

Keywords

  • Duchenne muscular dystrophy skeletal muscle
  • Neuronal nitric oxide synthase splice variants
  • Nitric oxide
  • nNOS
  • PDE5
  • Phosphodiesterase 5 inhibitors
  • sGC
  • Soluble guanylyl cyclase

ASJC Scopus subject areas

  • Biochemistry
  • Physiology
  • Clinical Biochemistry
  • Cancer Research

Cite this

Neuronal nitric oxide synthase (nNOS) splice variant function : Insights into nitric oxide signaling from skeletal muscle. / Balke, Jordan E.; Zhang, Ling; Percival, Justin M.

In: Nitric Oxide - Biology and Chemistry, Vol. 82, 01.01.2019, p. 35-47.

Research output: Contribution to journalReview article

@article{e72f77a264144c98a60869fe5b4de680,
title = "Neuronal nitric oxide synthase (nNOS) splice variant function: Insights into nitric oxide signaling from skeletal muscle",
abstract = "Defects in neuronal nitric oxide synthase (nNOS) splice variant localization and signaling in skeletal muscle are a firmly established pathogenic characteristic of many neuromuscular diseases, including Duchenne and Becker muscular dystrophy (DMD and BMD, respectively). Therefore, substantial efforts have been made to understand and therapeutically target skeletal muscle nNOS isoform signaling. The purpose of this review is to summarize recent salient advances in understanding of the regulation, targeting, and function of nNOSμ and nNOSβ splice variants in normal and dystrophic skeletal muscle, primarily using findings from mouse models. The first focus of this review is how the differential targeting of nNOS splice variants creates spatially and functionally distinct nitric oxide (NO) signaling compartments at the sarcolemma, Golgi complex, and cytoplasm. Particular attention is given to the functions of sarcolemmal nNOSμ and limitations of current nNOS knockout models. The second major focus is to review current understanding of cGMP-mediated nNOS signaling in skeletal muscle and its emergence as a therapeutic target in DMD and BMD. Accordingly, we address the preclinical and clinical successes and setbacks with the testing of phosphodiesterase 5 inhibitors to redress nNOS signaling defects in DMD and BMD. In summary, this review of nNOS function in normal and dystrophic muscle aims to advance understanding how the messenger NO is harnessed for cellular signaling from a skeletal muscle perspective.",
keywords = "Duchenne muscular dystrophy skeletal muscle, Neuronal nitric oxide synthase splice variants, Nitric oxide, nNOS, PDE5, Phosphodiesterase 5 inhibitors, sGC, Soluble guanylyl cyclase",
author = "Balke, {Jordan E.} and Ling Zhang and Percival, {Justin M.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.niox.2018.11.004",
language = "English (US)",
volume = "82",
pages = "35--47",
journal = "Nitric Oxide - Biology and Chemistry",
issn = "1089-8603",
publisher = "Academic Press Inc.",

}

TY - JOUR

T1 - Neuronal nitric oxide synthase (nNOS) splice variant function

T2 - Insights into nitric oxide signaling from skeletal muscle

AU - Balke, Jordan E.

AU - Zhang, Ling

AU - Percival, Justin M.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Defects in neuronal nitric oxide synthase (nNOS) splice variant localization and signaling in skeletal muscle are a firmly established pathogenic characteristic of many neuromuscular diseases, including Duchenne and Becker muscular dystrophy (DMD and BMD, respectively). Therefore, substantial efforts have been made to understand and therapeutically target skeletal muscle nNOS isoform signaling. The purpose of this review is to summarize recent salient advances in understanding of the regulation, targeting, and function of nNOSμ and nNOSβ splice variants in normal and dystrophic skeletal muscle, primarily using findings from mouse models. The first focus of this review is how the differential targeting of nNOS splice variants creates spatially and functionally distinct nitric oxide (NO) signaling compartments at the sarcolemma, Golgi complex, and cytoplasm. Particular attention is given to the functions of sarcolemmal nNOSμ and limitations of current nNOS knockout models. The second major focus is to review current understanding of cGMP-mediated nNOS signaling in skeletal muscle and its emergence as a therapeutic target in DMD and BMD. Accordingly, we address the preclinical and clinical successes and setbacks with the testing of phosphodiesterase 5 inhibitors to redress nNOS signaling defects in DMD and BMD. In summary, this review of nNOS function in normal and dystrophic muscle aims to advance understanding how the messenger NO is harnessed for cellular signaling from a skeletal muscle perspective.

AB - Defects in neuronal nitric oxide synthase (nNOS) splice variant localization and signaling in skeletal muscle are a firmly established pathogenic characteristic of many neuromuscular diseases, including Duchenne and Becker muscular dystrophy (DMD and BMD, respectively). Therefore, substantial efforts have been made to understand and therapeutically target skeletal muscle nNOS isoform signaling. The purpose of this review is to summarize recent salient advances in understanding of the regulation, targeting, and function of nNOSμ and nNOSβ splice variants in normal and dystrophic skeletal muscle, primarily using findings from mouse models. The first focus of this review is how the differential targeting of nNOS splice variants creates spatially and functionally distinct nitric oxide (NO) signaling compartments at the sarcolemma, Golgi complex, and cytoplasm. Particular attention is given to the functions of sarcolemmal nNOSμ and limitations of current nNOS knockout models. The second major focus is to review current understanding of cGMP-mediated nNOS signaling in skeletal muscle and its emergence as a therapeutic target in DMD and BMD. Accordingly, we address the preclinical and clinical successes and setbacks with the testing of phosphodiesterase 5 inhibitors to redress nNOS signaling defects in DMD and BMD. In summary, this review of nNOS function in normal and dystrophic muscle aims to advance understanding how the messenger NO is harnessed for cellular signaling from a skeletal muscle perspective.

KW - Duchenne muscular dystrophy skeletal muscle

KW - Neuronal nitric oxide synthase splice variants

KW - Nitric oxide

KW - nNOS

KW - PDE5

KW - Phosphodiesterase 5 inhibitors

KW - sGC

KW - Soluble guanylyl cyclase

UR - http://www.scopus.com/inward/record.url?scp=85057888021&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85057888021&partnerID=8YFLogxK

U2 - 10.1016/j.niox.2018.11.004

DO - 10.1016/j.niox.2018.11.004

M3 - Review article

C2 - 30503614

AN - SCOPUS:85057888021

VL - 82

SP - 35

EP - 47

JO - Nitric Oxide - Biology and Chemistry

JF - Nitric Oxide - Biology and Chemistry

SN - 1089-8603

ER -